Olmesartán Viso Farmacéutica (Olmesartan Medoxomil)

Olmesartan Medoxomil, the active ingredient in Olmesartán Viso Farmacéutica, is an angiotensin II receptor blocker presented as a tablet for oral use. It is used to treat hypertension in adult patients. GNH USA supplies Olmesartán Viso Farmacéutica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartán Viso Farmacéutica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxomil is an ARB that lowers blood pressure by interfering with the renin‑angiotensin‑aldosterone system.

- Hypertension: helps reduce systolic and diastolic blood pressure in adults. - Heart failure: used as part of combination therapy to improve cardiac output. - Diabetic nephropathy : may reduce protein uria and slow renal function decline. - Post‑myocardial infarction : assists in secondary prevention of cardiovascular events. - High‑risk vascular risk patients : lowers overall cardiovascular risk. - Chronic kidney disease : contributes to blood‑pressure control in patients with renal impairment.

Olmesartan Medoxomil is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea - Upper respiratory tract infection

Serious or Rare Side Effects: - Angio‑edema - Hyperkalemia - Acute kidney injury - Severe hypotension - Liver enzyme elevation - Myocardial infarction (rare)

Olmesartan Medoxomil should be used with caution in several clinical situations.

- Renal impairment: dose adjustment may be required. - Hepatic impairment: monitor liver function tests. - Electrolyte disturbances: watch for hyper‑kaliemia. - Pregnancy: contraindicated in the second and  - Breast ":    - Store at "); -  t

The   t  t